NewsRx

Search our medical news database

AIDS Vaccines

GlaxoSmithKline Biologicals announces start of human trial of novel HIV vaccine

Published in Vaccine Weekly, March 6th, 2002

GlaxoSmithKline Biologicals (GSK Biologicals) announces the start of the first trial in humans of its recombinant, adjuvanted candidate HIV vaccine - NefTat and gp 120 formulated with the proprietary adjuvant AS02.

The main objectives are to see if the candidate vaccine is safe and whether the human immune system responds to it.

The first human clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted in collaboration with the HIV Vaccine Trials Network (HVTN) in the U.S., following the encouraging results from rhesus monkey efficacy studies and other clinical studies on novel adjuvants. The HVTN is sponsored by the National...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook